These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 714218

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Anginin effect in cerebovascular disorders in the light of psychological studies].
    Michalska I.
    Neurol Neurochir Pol; 1979; 13(2):141-6. PubMed ID: 377119
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI, Tolstova LG.
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K, Oliva I, Linhart J, Prerovský I, Modr Z.
    Cas Lek Cesk; 1976 Aug 27; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A, Borri P, Parravicini R.
    Minerva Cardioangiol; 1975 Nov 27; 23(11):701-10. PubMed ID: 1223674
    [No Abstract] [Full Text] [Related]

  • 9. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L.
    Ther Hung; 1976 Nov 27; 24(2):67-71. PubMed ID: 982342
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P.
    J Pharm Sci; 1975 Jan 27; 64(1):261-9. PubMed ID: 1094102
    [No Abstract] [Full Text] [Related]

  • 19. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P.
    Minerva Cardioangiol; 1975 Apr 27; 23(4):261-9. PubMed ID: 1095958
    [No Abstract] [Full Text] [Related]

  • 20. [Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography].
    Motomiya T.
    Nihon Naika Gakkai Zasshi; 1970 Feb 10; 59(2):117-25. PubMed ID: 4910199
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.